Join
Live feed
·
INSIDERFilingvia Quantisnow
Revance Therapeutics Inc. logo

President & CEO Foley Mark J returned 112,619 shares to the company and was granted 84,686 shares, closing all direct ownership in the company (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RVNC· Revance Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RVNC (Revance Therapeutics Inc.) and more on Quantisnow.